{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:07:53Z","timestamp":1789891673212,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.eururo.2018.06.045","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T21:26:45Z","timestamp":1532035605000},"page":"540-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy"],"prefix":"10.1016","volume":"74","author":[{"given":"Mathieu F.","family":"Chevalier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dartiguenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Jichlinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Nardelli-Haefliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Derr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.06.045_bib0080","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: Recommendations from the International Bladder Cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.045_bib0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.045_bib0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CYPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.045_bib0095","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2018.06.045_bib0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2018.06.045_bib0105","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2018.06.045_bib0110","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nm.3485","article-title":"FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS","volume":"20","author":"Liu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2018.06.045_bib0115","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2018.06.045_bib0120","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/ijms18102186","article-title":"Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical Bacille Calmette-Guerin: a long-term follow-up study of a Japanese cohort","volume":"18","author":"Miyake","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2018.06.045_bib0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2006.08.078","article-title":"Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines","volume":"177","author":"Loskog","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.06.045_bib0130","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.06.045_bib0135","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.eururo.2018.06.045_bib0140","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2018.06.045_bib0145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2018.06.045_bib0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2017.06.012","article-title":"Systematic review of immune checkpoint inhibition in urological cancers","volume":"72","author":"Rijnders","year":"2017","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T21:19:57Z","timestamp":1539119997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818304731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0302283818304731"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.045","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}